This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Multiple Myeloma Peer-to-Peer
Multiple Myeloma Maintenance Therapy: What is the Optimal Duration?
The question is still debated because the data are sparse, but Dr. Holstein, of the University of Nebraska Omaha, encourages continuing maintenance for as long as possible. (1:56)
Fine-Tuning VTE Prophylaxis in Patients with Multiple Myeloma
Given the dearth of randomized controlled trials available with regard to VTE in patients with multiple myeloma, a simplified, expert-based approach to prophylaxis at various stages of MM, treated with contemporary MM regimens, should be followed.
Racial Differences in Multiple Myeloma Impact Outcomes
These investigators examined the prognostic significance of racial disparities and cytogenetic abnormalities in the development of multiple myeloma in patients younger than 50.
Multiple Myeloma: When Should Minimal Residual Disease be the Goal?
While minimal residual disease negativity is theoretically a good goal for all MM patients, the important question is whether treatments should be adjusted to accomplish this, explains Dr. Holstein, of University of Nebraska Omaha. (1:33)
Multiple Myeloma Trials Have a Gaping Hole
Although multiple myeloma usually develops in later life, studies devoted to the condition tend to recruit younger patients. Does this inhibit the progress of medical advances for the disease?
Circulating Tumor Cells May Inform Staging in Newly Diagnosed Multiple Myeloma
Evidence of bone marrow plasma cell clonal expansion is currently used in diagnosing multiple myeloma (MM), but the prognostic reliability of this approach has been debated. Perhaps there’s a better way.
Smoldering Multiple Myeloma: Predicting Disease Progression
In a recent study of patients with smoldering multiple myeloma (SMM), patterns of genetic mutations were shown to be associated with clinical outcomes and progression to MM.
Meet R2-ISS, A Multiple Myeloma Staging System Revision
The R-ISS for stratifying risk in multiple myeloma patients is outdated, and the risk of death or disease progression is heterogeneous among patients in the R-ISS II group. The newer staging system, R2-ISS, calculates a more accurate, simpler prognostic score.
In R/R Multiple Myeloma, cfDNA has Independent Predictive Value
In both test and validation cohorts, detection of tumor-positive cell-free DNA by low-pass whole genome sequencing was associated with significantly shorter progression-free survival in patients with relapsed/refractory multiple myeloma.
Jonathan L. Kaufman, MD, on Vaccinations in Patients with Multiple Myeloma
Dr. Kaufman answers our questions about vaccination strategies in these vulnerable patients.
In Multiple Myeloma, Underlying Biologic Differences Do Not Affect Clinical Outcomes
A recent study sought to compare genetic lesions between males and females to determine whether they would predict differences in progression-free survival and overall survival.
Evaluating Treatment Risks in Multiple Myeloma
A new systematic review and meta-analysis examined monthly risk for grade ≥3 infections, pneumonia, neutropenia—each assessed in front-line, maintenance, and relapsed/refractory multiple myeloma (MM) settings—across 31 studies.
Globulin Gap on Routine Lab Tests: When is it a Concern?
According to Sarah Holstein, MD, PhD, of the University of Nebraska Omaha, globulin gaps are not always a cause for concern, but there are times when it's best to err on the side of caution. (2:30)
In Multiple Myeloma, Give the Appropriate 3-4 drug Regimen from the Start
New research from the Mayo Clinic suggests that your first shot should always be your best start when initiating multiple myeloma treatment.
In Multiple Myeloma, Moving Toward Better Repair of Vertebral Fractures
Investigators studied whether adding surgery to RT therapy improved outcomes and quality of life in this group of patients.
Restoration of Humoral Immunity in Patients Vaccinated Post-AHCT Is Associated With Improved Progression-Free and Overall Survival
A recent study examined the feasibility and effectiveness of vaccination in patients post-AHCT and whether it helped restore humoral immunity.
Association Between Kidney Function, Proteinuria and the Risk of Multiple Myeloma
Researchers found that decreased renal function was associated with a significantly higher risk of developing multiple myeloma.